NCT01347723CompletedNot Applicable
Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Open Access Trial
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Mayo Clinic
- Enrollment
- 194
- Locations
- 1
- Primary Endpoint
- Change in pain on a 0-10 numerical rating scale.
Study Overview
Brief Summary
This pilot clinical trial studies scrambler therapy in treating pain and peripheral neuropathy in patients previously treated with chemotherapy. Scrambler therapy may help relieve pain from peripheral neuropathy caused by chemotherapy
Detailed Description
OBJECTIVES:
I. To record the types of patients that we treat, along with the reported efficacy and potential toxicity associated with scrambler therapy.
II. To get experience with patient reported outcome measurement tools that we use in this trial, including a report of analgesic use.
OUTLINE: Patients undergo scrambler therapy for 30 minutes daily for up to 10 consecutive days. Treatment continues in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up for 10 weeks.
III. To explore neurologic testing changes in patients receiving scrambler therapy.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pain or symptoms of neuropathy or pain of >= 1 month (30 days) duration for which the patient wants intervention
- •Participants have to relate that tingling or pain was at least a four out of ten problem during the prior week, on a 0-10 scale where zero was no problem and ten was the worst possible problem and expected to have tingling or pain of at least 4/10 at the time of the first treatment
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0, 1, or 2
- •Life expectancy >= 3 months (90 days)
- •Case review by the study chair, or designate, as a case where treatment should be tried.
- •Ability to complete questionnaire(s) by themselves or with assistance - Ability to provide informed written consent
Exclusion Criteria
- •Pregnant women
- •Patients with implantable drug delivery systems, e.g. Medtronic Synchromed
- •Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, aneurysm clips, vena cava clips and skull plates; (metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed as are central venous access devices)
- •Patients with a history of myocardial infarction or ischemic heart disease within the past six months
- •Patients with history of epilepsy, brain damage, use of anti-convulsants for seizure prevention, concurrently using ketamine, symptomatic brain metastases; Note: anti-convulsant use is allowed for neuropathy and heart failure (HF) if on a stable dose
- •Skin conditions such as open sores that would prevent proper application of the electrodes
- •Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study
- •Currently on gabapentin or pregabalin Note: (because of data that support that patients don't do as well when on gabapentin or pregabalin, all patients on these medications will be weaned off of them prior to study initiation. The study team will provide instructions on how to do this).
Outcomes
Primary Outcomes
Change in pain on a 0-10 numerical rating scale.
Time Frame: 3 years
Secondary Outcomes
- Changes in neurologic function will be done by Neurometer Current Perception Threshold (CPT) testing and with a Rydel-Seiffer graduated tuning fork.(3 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by ChemotherapyPainPeripheral NeuropathyNCT01290224Mayo Clinic10
Active, not recruiting
Not Applicable
Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot StudyPeripheral NeuropathyNCT05357469M.D. Anderson Cancer Center30
Completed
Not Applicable
Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus InfectionDermatologic ComplicationsPainViral InfectionNCT01347736Mayo Clinic10
Completed
Not Applicable
Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic PainChemotherapy-Induced Peripheral NeuropathyMalignant NeoplasmNCT04239976M.D. Anderson Cancer Center16
Completed
Not Applicable
Scrambler Trial for Pain in NMOSDNeuromyelitis OpticaNCT03452176Johns Hopkins University22